Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Morocco to roll out...

    Morocco to roll out antimalarials against coronavirus

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-03-26T09:15:24+05:30  |  Updated On 26 March 2020 9:15 AM IST
    Morocco to roll out antimalarials against coronavirus

    Rabat: Morocco has authorized hospitals to use antimalarial drugs in treating the new coronavirus, according to a document seen by AFP, as scientists urge caution over encouraging results from small trials.

    The Moroccan health ministry on Monday gave hospitals and regional health directors the green light to start using hydroxychloroquine and related compound chloroquine "in the care of confirmed COVID-19 cases".

    In a message seen by AFP, it said that "efforts have been made to ensure the availability of these medicines", urging caution in how the stocks are managed.

    Rabat last week ordered the Moroccan branch of French drugmaker Sanofi to hand over its entire stock of Nivaquine and Plaquenil, both of which contain chloroquine.

    Studies in France and China have found that the drug helped patients suffering from the COVID-19 illness, and France on Monday ordered its use in severe cases.

    US President Donald Trump on Monday said chloroquine could be a "gift from God".

    He has been criticized by scientists for overhyping the drug, and on Monday the World Health Organization urged caution over its use.

    NBC later reported that a woman in Arizona who heard Trump talk about chloroquine ended up in the hospital and her husband died after they took a form of chloroquine she had used to treat her koi fish.

    Authorities in Nigeria said hospitals had seen cases of chloroquine poisoning after Trump's comments.

    Experts have urged the public to remain cautious until larger clinical trials validate the smaller studies.

    In its note, Morocco's health ministry said it took its decision after consulting with a scientific committee that recommended prescribing chloroquine along with another drug called azithromycin.

    Morocco's transport minister, Abdelkader Amara, who tested positive for the new coronavirus on March 14, has already said he was taking Nivaquine.

    "My health is stable. I have no fever or respiratory symptoms. The headaches are almost gone. I just feel a little tired," he told private radio station Medi 1.

    Morocco has recorded 143 cases of the COVID-19 illness, with four dead. The country has three screening centers and 1,642 intensive care beds for 35 million inhabitants.

    Read also: Gilead puts emergency access to experimental coronavirus drug on hold amid surging demand


    coronavirusantimalarialcovid-19
    Source : AFP

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok